The Department of Health and Human Services Office of Inspector General Feb. 18 released a report that found about 40% of Medicare enrollees who began opioid use disorder treatment with buprenorphine continued with it for at least six months in office-based settings. Those who did not continue treatment were more likely to have died for any cause during the study period than those who did. One-third of enrollees who began treatment with buprenorphine received at least one behavioral therapy service; those who did not receive these services were less likely to continue treatment. Few enrollees received services paid for by Medicare aimed at sustaining access to treatment, such as counseling and care coordination in an office-based setting or initiation of treatment in the emergency department.

Related News Articles

Headline
A new report from KFF reveals that Medicare Advantage enrollees had access to just 48% of the physicians available to Traditional Medicare beneficiaries in…
Headline
The AHA Oct. 23 recommended changes to the Centers for Medicare & Medicaid Services’ Wasteful and Inappropriate Services Reduction model to address…
Headline
The Centers for Medicare & Medicaid Services has released an operational guide for Medicare-enrolled providers and suppliers on the Wasteful and…
Headline
A report by the Department of Health and Human Services Office of the Inspector General found that many Medicare Advantage and Medicaid managed care plans…
Headline
Medicare open enrollment for 2026 began Oct. 15 and runs through Dec. 7. During the annual enrollment period, Medicare-eligible individuals can check their…
Headline
The AHA Oct. 3 responded to the Medicare Payment Advisory Commission’s recent analysis on the financial impacts of Medicare Advantage enrollment growth on…